TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter
TGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages include a shorter infusion time, lower malignancy risks, and a more favorable price compared to Ocrevus. TGTX's financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite cash runway.
Why TG Therapeutics Stock Was Soaring This Week
Following news of an estimates-topping fourth quarter, TG Therapeutics (TGTX 9.24%) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotech's share price had risen by almost 27% week to date.
TG Therapeutics: A Wonderful Hold
TG Therapeutics, Inc. stock is surging due to strong financial performance and a promising outlook, driven by the success of its flagship drug, Briumvi. Revenue for Q4 reached $107.3 million, up 146% year-over-year with 2024 total revenue at $313.7 million, largely from Briumvi sales. The company achieved a net income of $23.3 million in Q4, a significant turnaround from a net loss in the previous year, with positive cash flow.
TG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald Michael DiFiore - Evercore ISI Ed White - H.C. Wainwright Eric Joseph - JPMorgan Mayank Mamtani - B.
TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide
TG Therapeutics stock skyrocketed Monday after easily beating fourth-quarter sales expectations and issuing a bullish outlook for 2025. The post TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide appeared first on Investor's Business Daily.
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TG Therapeutics: Entering 2025 With Increased Investor Expectations
TG Therapeutics presented at the JP Morgan Healthcare conference this month and CEO Weiss provided commercial and pipeline updates. Briumvi's strong Q4 2024 performance, with $103.6 million in net sales, and 2025 outlook highlight its growth potential despite recent new competition from Roche's Ocrevus Zunovo. Pipeline updates include subcutaneous Briumvi entering phase 3 trials in mid-2025 and new trials to improve IV Briumvi's convenience, alongside expansion into myasthenia gravis.
TG Therapeutics: 2025 Revenues Will Smash Expectations
TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million implies slower growth, but management and data suggest potential for significantly higher revenue, possibly reaching $605 million. CEO comments and Q4 performance indicate sustained 15-20% new patient growth, bolstered by upcoming advertisements and increased visibility among key opinion leaders.
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst
TG Therapeutics is already marketing an IV infusion of Briumvi, but is also developing a subcutaneous form, which could help it compete with other multiple sclerosis drugs. The company expects to report initial data on the subcutaneous form of Briumvi in early 2025, which could be positive given the company's upbeat statements on its prospects. While the company has approved a $100M share buyback, it only bought back $2.1M in Q3'24. Further buybacks could limit downside in the stock.
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in line with management expectations of a softer Q3. Now we wait for the important updates in early 2025 — preliminary Q4 net sales of Briumvi, the guidance for 2025, and the preliminary results from subcutaneous Briumvi's trial.
